Become a Member and get exclusive discounted Prices and Deals.
Each unique profile includes:
- Whole genome/exome sequencing of 20,000 genes and 3 billion base pairs
- Whole transcriptome sequencing of more than 200,000 RNA transcripts
- Comparison of a patient’s tumor genome to their normal genome and provides pharmacogenomic analysis for potential drug toxicity and/or interactions
GPS Cancer offers molecular insights into therapies that may benefit patients—including FDA-approved therapies and active clinical trials—as well as therapies to which the cancer may be resistant. All GPS Cancer sequencing is performed in CAP-accredited, CLIA-certified labs.